Naresh Jain, PhD

CEO at NJ Bio

Speaker

Dr. Jain is the Founder and CEO of NJ Bio, Inc., a premier CRO/CDMO with a strong focus on antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), mRNA, siRNA, and other nucleic acid-based therapeutics. He has led numerous programs involving complex bioconjugation, linker-payload design, oligonucleotide conjugation, and GMP manufacturing. He also founded The Chemistry Research Solution (TCRS), acquired by Abzena in 2015, and spent over a decade in medicinal chemistry roles at Johnson & Johnson. Dr. Jain earned his Ph.D. from Boston University, completed postdoctoral research at The Scripps Research Institute, and executive training through the Advanced Management Program at The Wharton School. He is the co-author of over 70 scientific publications and patents, with deep expertise across drug discovery, bioconjugation, and ADC/AOC developments.